Market capitalization | $1.00b |
Enterprise Value | $124.41m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.37 |
P/S ratio (TTM) P/S ratio | 27.16 |
P/B ratio (TTM) P/B ratio | 1.21 |
Revenue growth (TTM) Revenue growth | 48.46% |
Revenue (TTM) Revenue | $36.97m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
15 Analysts have issued a Bicycle Therapeutics Plc forecast:
15 Analysts have issued a Bicycle Therapeutics Plc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 37 37 |
48%
48%
|
|
Gross Profit | 30 30 |
60%
60%
|
|
EBITDA | -228 -228 |
22%
22%
|
EBIT (Operating Income) EBIT | -235 -235 |
21%
21%
|
Net Profit | -167 -167 |
3%
3%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
Head office | United Kingdom |
CEO | Kevin Lee |
Employees | 284 |
Founded | 2009 |
Website | bicycletherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.